AHK-Cu Administration Routes in Research: What Studies Used

What "administration route" means in copper-peptide research

In the published literature, the route of administration is a methods detail: it records how a compound reached the tissue being studied. For copper-binding tripeptides such as GHK-Cu and the closely related AHK-Cu, the route chosen in a given paper usually followed the question being asked. Skin and wound studies applied material directly to the surface or embedded it in a dressing. Cell-culture work added peptide to media, which is not an administration route at all in the clinical sense. Reviews of injectable peptide therapy discussed parenteral delivery as a category, largely in the context of unapproved use.

This page describes those study methods in third person and does not describe how any substance should be used. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

Where AHK-Cu sits in the indexed record

AHK-Cu (alanine–histidine–lysine bound to copper) is frequently discussed alongside GHK-Cu (glycine–histidine–lysine–copper), the tripeptide with a far larger indexed literature. A 2008 review characterised the human tripeptide GHK as a copper-binding molecule involved in tissue remodelling (PMID 18644225). A 2018 review of gene-expression data described regenerative and protective actions attributed to the GHK-Cu peptide (PMID 29986520), and a 2020 review examined the potential of GHK as an anti-aging peptide (PMID 35083444).

Readers looking for AHK-Cu-specific pharmacokinetics — a plasma curve after subcutaneous injection, an oral bioavailability percentage, a nasal absorption fraction — will not find that in the peer-reviewed sources summarised here. Where this page discusses a route, it reports what a study or review actually did or discussed, and where the record is silent it says so rather than filling the gap.

Topical application: the dominant route in the tripeptide literature

Topical delivery is by far the most commonly described route for copper tripeptides, because the tissues of interest — skin, wounds, hair follicles — are directly accessible. A 2025 review of topically applied GHK as an anti-wrinkle peptide examined the advantages and the problems of that route, including questions about delivery through the skin barrier (PMID 39963574). That review is a useful illustration of a recurring theme: researchers reported that a peptide's behaviour in a dish does not automatically predict what happens when the same molecule is placed on intact skin, where stratum corneum penetration, formulation vehicle and copper coordination all matter.

The same review framework applies conceptually to AHK-Cu, which appears in cosmetic ingredient literature rather than in controlled clinical pharmacology studies. Descriptions of copper-tripeptide activity in skin remodelling contexts trace back to the mechanistic literature on GHK (PMID 18644225) rather than to head-to-head route comparisons.

Local delivery systems: hydrogels, dressings and scaffolds

A second cluster of studies did not use a classical "route" at all but built the peptide into a material placed at the target site. A 2025 study described a food-derived tripeptide–copper self-healing hydrogel developed for infected wound healing, with the copper peptide incorporated into the gel matrix rather than administered systemically (PMID 39902373). A separate 2025 report described a dimeric copper peptide incorporated into a hydrogel and evaluated for promoting diabetic wound healing (PMID 40592840).

Researchers gave consistent reasons for this design choice in such work: local delivery keeps copper concentrated where it is wanted, avoids first-pass metabolism, and allows sustained release from a matrix instead of a single bolus. It also sidesteps the systemic copper-handling questions that arise when a copper complex is injected. A 2024 study took a different materials angle again, describing copper-induced supramolecular peptide assemblies and reporting multi-pathway cell death and tumour inhibition in the models used (PMID 38837577) — an oncology-directed design, not a cosmetic or regenerative one.

Injectable routes: what the review literature discusses

Questions about subcutaneous, intramuscular and intraperitoneal delivery of copper tripeptides are common, but the indexed sources available here address injectable peptides as a class rather than AHK-Cu specifically. A 2026 primer on injectable peptide therapy written for orthopaedic and sports medicine physicians surveyed the injectable peptide landscape and the clinical questions it raises (PMID 41476424). A 2026 review of therapeutic peptides in orthopaedics covered applications, challenges and future directions, with delivery and translation among the recurring obstacles (PMID 41490200).

Two further 2026 reviews addressed the same territory from the safety side. One examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance (PMID 41966639), and another reviewed peptide supplements and their therapeutic applications in sports medicine (PMID 42578445). Across those reviews, the recurring point is that many peptides circulating outside regulated channels have not been evaluated in controlled human trials at the doses and routes being discussed informally.

Why researchers pick a parenteral route at all

The standard scientific rationale, as reflected in the injectable peptide reviews, is that small peptides are poorly suited to oral delivery because of gastrointestinal proteolysis and limited intestinal absorption, so preclinical work often uses subcutaneous or intraperitoneal injection to guarantee systemic exposure. Intraperitoneal dosing in particular is a rodent-convenience route with no clinical counterpart. None of these considerations constitute a description of how AHK-Cu has been given to humans, because the sources here do not report that.

Oral and intranasal formulations

The verified sources summarised on this page do not report oral or intranasal administration studies of AHK-Cu. Copper tripeptides do appear in ingestible contexts indirectly — the hydrogel study describing a food-derived tripeptide–copper complex started from a dietary peptide source before formulating it into a wound dressing (PMID 39902373) — but that is a materials origin story, not evidence of oral systemic delivery. Where a claim about oral or nasal bioavailability cannot be traced to a published study, this page omits it rather than estimating.

Measuring copper peptides: an analytical problem, not just a delivery one

One reason route-comparison data are scarce for copper tripeptides is that measuring them is difficult. A 2018 investigation applied LC-MS/MS and NMR to the copper peptide hepcidin-25, characterising the peptide–copper interaction with analytical methods (PMID 30072660). Copper-binding peptides can exchange metal, degrade, or bind serum proteins, which complicates the quantification of intact complex in plasma. Without validated assays, meaningful bioavailability percentages by route are hard to generate — which is part of why the tripeptide field leaned toward local application and materials-based delivery in the first place.

Summary table: routes as they appeared in the literature

Adverse Events and Safety: What Studies Report

The sources here do not report a route-by-route adverse-event profile for AHK-Cu. What is available is the broader peptide safety literature. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance examined safety alongside efficacy and highlighted the gap between marketed claims and controlled evidence (PMID 41966639). A 2026 review of peptide supplements in sports medicine similarly assessed therapeutic applications against the quality of supporting data (PMID 42578445), and the 2026 orthopaedics review discussed challenges that remain before therapeutic peptides can be routinely applied (PMID 41490200).

The injectable peptide primer written for physicians framed injection-based peptide use as an area requiring clinical caution and awareness of regulatory status (PMID 41476424). Copper-specific considerations — systemic copper load, redox chemistry, tissue accumulation — are discussed mechanistically in the GHK reviews (PMID 29986520) but not as clinical safety endpoints in human trials of AHK-Cu.

Regulatory context

AHK-Cu is not an approved drug product. Copper tripeptides appear in cosmetic formulations under cosmetic ingredient rules, while material sold for laboratory work is typically labelled research use only. The peptide reviews aimed at clinicians distinguish repeatedly between approved peptide medicines and the much larger set of unapproved compounds circulating in performance and wellness settings (PMID 41966639). This section is regulatory background, not legal advice.

What the evidence does not establish

• No published human pharmacokinetic comparison of AHK-Cu across oral, nasal, subcutaneous, intramuscular or intraperitoneal routes appears in the sources summarised here.
• No bioavailability percentage by route can be cited for AHK-Cu from these papers.
• Mechanistic findings for GHK-Cu (PMID 35083444) describe a related but distinct molecule and do not transfer automatically to AHK-Cu.
• Hydrogel and dressing studies evaluated local delivery in wound models (PMID 40592840) and were not designed to inform systemic dosing.

Anyone reading route claims about this peptide can usefully ask three questions of the source: what species was studied, whether the peptide was AHK-Cu or GHK-Cu, and whether the delivery was local or systemic. Those three details separate most of the accurate summaries from the inaccurate ones.

References

• The human tri-peptide GHK and tissue remodeling (Journal of Biomaterials Science, Polymer Edition, 2008)
• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018)
• Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (International Journal of Molecular Sciences, 2018)
• The potential of GHK as an anti-aging peptide (Aging Pathobiology and Therapeutics, 2020)
• Copper-Induced Supramolecular Peptide Assemblies for Multi-Pathway Cell Death and Tumor Inhibition (Angewandte Chemie International Edition, 2024)
• Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing (Biomaterials Research, 2025)
• Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective (BioImpacts, 2025)
• Dimeric copper peptide incorporated hydrogel for promoting diabetic wound healing (Nature Communications, 2025)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)